Advances in the Diagnosis and Treatment of Lung Adenocarcinoma–Part II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 24 October 2024 | Viewed by 1633

Special Issue Editors


E-Mail Website
Guest Editor
Department of Thoracic Surgery, Hammersmith Hospital, London, UK
Interests: lung cancer; minimally invasive thoracic surgery; translational medicine; health policy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Imperial College Healthcare NHS Trust, London, UK
2. 424 General Military Hospital, Thessaloniki, Greece
Interests: cardiothoracic surgery; thoracic surgical oncology; lung cancer; tracheal disease; coronary artery disease; cardiac valve disease; thoracic trauma; military medicine; translational cardiovascular medicine; surgical education and simulation; health policy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020. The histological pattern of lung cancer changed significantly over a period of only a few decades, with a decrease in squamous cell carcinoma and a sharp rise in adenocarcinoma. Currently, adenocarcinoma represents the most common histologic type of pulmonary tumors, accounting for more than 65% of all lung cancers. Of interest, it is also the most common form of lung cancer in people who have never been smokers. With the recent introduction of lung cancer screening programs and the increasing detection of adenocarcinoma spectrum lesions (e.g., adenocarcinoma in situ, minimally invasive adenocarcinoma), the number of newly diagnosed cases is expected to further rise.

Apart from changes in the epidemiology and biology of lung cancer, significant advances have recently occurred in the diagnosis and treatment of the disease. The discovery of treatable oncogenic alterations has led to the routine implementation of molecular testing in the diagnostic evaluation of patients with lung adenocarcinoma. Indeed, an increasing number of targetable gene alterations has been recently identified, enabling individualized therapies that have demonstrated remarkable responses in selected patients. Targeted therapies were initially used for the management of advanced lung adenocarcinoma, but they have also recently shown promising results in early disease as part of multimodality treatments. This success of targeted therapies has resulted in ongoing efforts to identify and therapeutically target other driver mutations. Furthermore, important progress has been achieved in the development of immunotherapies, which now constitute the first line treatment of advanced, wild-type lung adenocarcinomas. Moreover, a paradigm shift in the surgical management of small, peripheral adenocarcinomas, which may radiologically manifest as subsolid lung nodules, has been recently observed. Sublobar resections in the form of segmentectomy or even wedge resection have been increasingly adopted by thoracic surgeons as a valid alternative to the traditional lobectomy. Such lesions may be also successfully treated with stereotactic ablative radiotherapy, which is being currently investigated as an alternative to surgical resection.

It becomes evident that the landscape of lung adenocarcinoma is transforming rapidly. This has created great opportunities for research in diagnosis and treatment; however, it has also presented challenges to clinicians, who are often presented with an excessive amount of new information. This Special Issue, entitled “Advances in the Diagnosis and Treatment of Lung Adenocarcinoma”, aims to provide the readers of the Journal of Clinical Medicine with concise, high-quality, and up-to-date knowledge, as well as to present evidence thus far unpublished on this topic. Therefore, it welcomes both reviews and original articles. By discussing the advances in the diagnosis and treatment of lung adenocarcinoma and identifying avenues for future research, this Special Issue will be a valuable resource for researchers, clinicians, and patients alike.

Dr. Marco Scarci
Dr. Savvas Lampridis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • chemotherapy
  • immunotherapy
  • lung adenocarcinoma
  • lung surgery
  • molecular targeted therapy
  • non-small cell lung cancer
  • radiotherapy
  • screening

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

13 pages, 1076 KiB  
Systematic Review
Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review
by Ionas Papassotiriou, Antonios Kapogiannatos, Christos Makatsoris, Sabrina Bakogeorgou, Ioanna Mantogiannakou, Emmanouela Roussou, Georgios Souras, Dimitris Liakas, Theodoros N. Sergentanis, Maria Gavriatopoulou and Ioannis Ntanasis-Stathopoulos
J. Clin. Med. 2024, 13(18), 5489; https://doi.org/10.3390/jcm13185489 - 16 Sep 2024
Viewed by 1284
Abstract
Objectives: This systematic review aimed to examine the efficacy and safety profile of amivantamab in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR mutations. Methods: Three scientific databases, PubMed, Cochrane library and ClinicalTrials.gov were searched for relevant articles up [...] Read more.
Objectives: This systematic review aimed to examine the efficacy and safety profile of amivantamab in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR mutations. Methods: Three scientific databases, PubMed, Cochrane library and ClinicalTrials.gov were searched for relevant articles up until 30 June 2024. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and ≥3 grade adverse events (AE) were the outcomes of interest. Results: Five clinical trials were included in this systematic review, reporting data from 1124 patients (safety population; n = 1091 efficacy population), who received amivantamab as a monotherapy or in combination with other treatments, both in a first-line and in a relapsed/refractory setting. The median PFS for groups of patients that received amivantamab ranged from 4.3 to 8.3 months, while the lowest observed OS was 10.2 months. The ORR ranged from 30% to 73%. The rate of grade 3 or higher AEs ranged from 35% to 92%, while serious AEs ranged from 29% to 52%. Infusion-related reactions (IRRs) ranged from 42% to 78% among patients that received amivantamab intravenously, while a 13% IRR rate was found in a group of patients that received amivantamab subcutaneously. Conclusions: Current evidence suggests that amivantamab is an effective treatment option for patients with advanced or metastatic NSCLC with EGFR mutations. Amivantamab-based combinations may prolong survival both in the treatment of naïve patients and those who have progressed on chemotherapy or tyrosine kinase inhibitors. Full article
Show Figures

Figure 1

Back to TopTop